TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
ZTS

Zoetis Inc

Healthcare · Drug Manufacturers - Specialty & Generic

72.70$ -6.0% vs. previous close Closing price · As of: Aug 7, 2026

Statements

Segments

US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Zoetis Inc (ZTS). It shows which part of the business is growing — and which one is holding it back.

Revenue by business segment

Revenue by business segment — ZTS
Segment 2020 2021 2022 2023 2024 2025
United States Segment $3.56B 54.0% $4.04B 52.5% · +13.6% $4.31B 54.0% · +6.7% $4.56B 53.8% · +5.6% $5.07B 55.3% · +11.4% $5.10B 54.5% · +0.5%
International Segment $3.04B 46.0% $3.65B 47.5% · +20.3% $3.68B 46.0% · +0.8% $3.91B 46.2% · +6.2% $4.10B 44.7% · +4.9% $4.25B 45.5% · +3.7%

Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.

Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.

Data as of: August 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?